RH5.1/Matrix-M Malaria Vaccine Shows Promise as Blood-Stage Defense
Key Insights
A Phase IIb trial of the RH5.1/Matrix-M vaccine shows 55% efficacy in preventing clinical malaria (search) over six months in young children.
The vaccine also demonstrated over 80% efficacy against high levels of malaria (search) parasites, suggesting potential in preventing severe cases.
RH5.1/Matrix-M targets the blood-stage of malaria (search), complementing existing vaccines that target the liver-stage of the parasite.
The RH5.1/Matrix-M vaccine is emerging as a promising candidate in the fight against malaria (search), particularly as a blood-stage intervention. Results from a Phase IIb trial indicate that the vaccine is well-tolerated and offers effective protection against clinical malaria in young children. The study, conducted in Burkina Faso, involved over 360 children aged 5 to 17 months and demonstrated a 55% efficacy in preventing clinical malaria over a six-month period when administered in a delayed third-dose regimen (0, 1, and 5 months).
Clinical Efficacy and Impact
The RH5.1/Matrix-M vaccine not only reduced the incidence of clinical malaria (search) but also demonstrated over 80% efficacy against high levels of malaria parasites in the blood. This suggests that the vaccine could be particularly effective in preventing severe cases of the disease. According to Professor Angela Minassian from the University of Oxford, targeting the blood-stage of malaria with this vaccine aims to significantly reduce the number of severe cases and deaths.
Complementary Approach to Existing Vaccines
Currently, the WHO prequalified malaria (search) vaccines, such as GSK’s Mosquirix and the Serum Institute of India’s R21/Matrix-M, target the liver-stage of the parasite. These vaccines are effective at preventing parasites from entering the blood. However, if these vaccines fail, and parasites slip through, the disease will develop. The RH5.1/Matrix-M vaccine offers a complementary approach by targeting the blood-stage, providing a second line of defense. “Adding RH5.1/Matrix-MTM to these licensed vaccines should provide a vital second line of defense, achieving even higher levels of protection,” said Professor Minassian.
Safety and Tolerability
The Phase IIb trial also highlighted the safety and tolerability of the RH5.1/Matrix-M vaccine. The most common adverse events were mild, including swelling at the injection site (3%) and fever (14%). These rates compare favorably to those observed in the Phase III trials of Mosquirix and R21/Matrix-M.
Future Directions
While the RH5.1/Matrix-M vaccine shows promise, further research is needed to evaluate its long-term efficacy and impact on malaria (search) transmission. According to GlobalData, there are 11 other malaria vaccines currently in Phase II development. The RH5.1/Matrix-M vaccine has the potential to be the first blood-stage malaria vaccine brought to market and could be a much-needed addition to the currently available malaria vaccines.